Diagnostics and drug therapy for acid-related disease in the population of two Norwegian municipalities;Syrerelatert sykdom hos befolkningen i to sørlandskommuner - Diagnostikk og legemiddelbehandling

Tidsskrift for den Norske Laegeforening

Volumn 121, Issue 5, 2001, Pages 557-562

  Vetvik, Kåre ^a,b   Straand, Jørund ^a,c  

^a UNIVERSITY OF BERGEN   (Norway)

^b Mandal Sykehus ^*  (Norway)

^c UNIVERSITY OF OSLO   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ANTACID AGENT; CIMETIDINE; CISAPRIDE; FAMOTAL; FAMOTIDINE; GASTROBITAN; LANSOPRAZOLE; OMEPRAZOLE; PECIDIN; RANACID; RANITIDINE;

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; DIAGNOSTIC PROCEDURE; DRUG INDICATION; DYSPEPSIA; ENDOSCOPY; FEMALE; HEALTH INSURANCE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; NORWAY; PHARMACY; PRACTICE GUIDELINE; PRESCRIPTION; REIMBURSEMENT; RETROSPECTIVE STUDY; SCHOOL CHILD; STOMACH ACID;

ADOLESCENT; ADULT; AGED; ANTI-ULCER AGENTS; CHILD; DRUG UTILIZATION; DYSPEPSIA; ENDOSCOPY, GASTROINTESTINAL; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL DISEASES; HISTAMINE H2 ANTAGONISTS; HUMANS; MIDDLE AGED; NORWAY; PEPTIC ULCER; PRESCRIPTIONS, DRUG; RETROSPECTIVE STUDIES;

EID: 0035120346     PISSN: 00292001     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Statistical abstract of the United States: 1990. Table 114.110 utg. Washington D.C.: U.S. Bureau of the Census, 1990.
2. Modem medicines: saving life and money. Washington D.C.: Pharmaceutical Manufacturing Association, 1990: 2.
3. 2-antagonist treatment. Scand J Gastroenterol 1986; 21 (suppl 121): 46-52.
4. 2-receptor antagonists. Standard therapy for acid-peptic diseases (second of two parts). N Engl J Med 1990; 323:1749-55.
5. Lundell L. Pharmacotherapy of gastro-oesophageal reflux disease. I: Strandberg K, Westbye O, Beerman B, Wærsted A, red. Treatment of ulcer and gastro-oesophageal reflux. Workshop. Stockholm/Oslo: Läkemedelsverket/Statens legemiddelkontroll, 1994; I: 145-65.
6. Forskrift om stønad til dekning av utgifter til viktige legemidler og spesielt medisinsk utstyr. I: Tørisen HM, red. Felleskatalog over farmasøytiske spesialpreparater registrert i Norge 1992/93. 34. utgave. Oslo: Felleskatalogen A/S, 1992.
7. Øydvin K, red. Legemiddelforbruket i Norge 1990-1994. Oslo: Norsk medisinaldepot, 1995.
8. Labenz J, Börsch G. Highly significant change of the clinical course of relapsing and complicated peptic ulcer disease after cure of Helicobacter pylori infection. Am J Gastroenterol 1994; 89: 1785-8.
9. Dunn OJ. Multiple comparisons using rank sums. Technometrics 1964; 5: 241-52.
10. Goudie BM, Mckenzie PE, Cipriano J, Griffin EM, Murray FE. Repeat prescribing of ulcer healing drugs in general practice-prevalence and underlying diagnosis. Aliment Pharmacol Ther 1996; 10: 147-50.
11. Bodger K, Daly MJ, Heatly RV. Prescribing patterns for dyspepsia in primary care: a prospect ive study of selected general practitioners. Aliment Pharmacol Ther 1996; 10: 889-95.
12. Wilhelmsen I, Weberg R, Berstad K, Hausken T, Hundal O, Berstad A. Helicobacter pylori eradication with bismuth subnitrate, oxytetracycline and metronidazole in patients with peptic ulcer disease. Hepato-Gastroenterol 1994; 41: 43-7.
13. Lauritsen K, Rutgersson K, Boiling E, Brunner G, Eriksson S, Galmiche JP et al. Omeprazole and ranitidine in the prevention of relapse in patients with duodenal ulcer disease. Can J Gastroenterol 1999; 13: 806-13.
14. Mendeloff AI. Chairman's introduction. Scand J Gastroenterol 1980; 15 (suppl 63): 145-8.
15. Petersen H. the prevalence of gastro-oesophageal reflux disease. Scand J Gastroenterol 1995; 30 (suppl 211): 5-6.
16. Boutet R, Wilcock M, Mackenzie I. Survey on repeat prescribing for acid suppression drugs in primary care in Cornwall and the Isles of Scilly. Aliment Pharmacol Ther 1999; 13: 813-7.
17. Lööf L, Götell Å, Elfberg B. The incidence of reflux oesophagitis. A study of endoscopy reports from a defined catchment area in Sweden. Scand J Gastroenterol 1993; 28: 113-8.
18. Ramirez B, Richter JE. Review article: promotility drugs in the treatment of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1993; 7: 5-20.
19. Klinkenberg-Knol EC, Festen HP, Meuwissen SG. Pharmacological management of gastrooesophageal reflux disease. Drugs 1995; 49: 695-710.
20. Hatlebakk JG, Hyggen A, Madsen PH, Walle PO, Schulz T, Mowinckel P et al. Heartburn treatment in primary care: randomised, double blind study for 8 weeks. BMJ 1999; 319: 550-3.
21. Hatlebakk JG, Berstad A. Pharmacokinetic optimisation in the treatment of gastro-oesophageal reflux disease. Clin Pharmacokinet 1996; 31: 386-406.
22. Katz PO. Treatment of gastrooesophageal reflux disease: use of algorithms to aid in management. Am J Gastroenterol 1999; 94 (suppl 11): 3-10.
23. Forskrift om stønad til dekning av utgifter til viktige legemidler og spesielt medisinsk utstyr. I: Tørisen HM, red. Felleskatalog over farmasøytiske spesialpreparater registrert i Norge 1999.41. utgave. Oslo: Felleskatalogen A/S, 1999: 15f-16f.
24. Colin-Jones DG. Dyspepsia update. Scand J Gastroenterol 1995; 30 (suppl 210): 32-5.
25. Tibblin G. Introduction to the epidemiology of dyspepsia. Scand J Gastroenterol 1985; 20 (suppl 109): 29-33.
26. Rubin GP, Contractor B, Bramble MG. The use of long-term acid-suppression therapy. Br J Clin Pract 1995; 49: 119-20.
27. Strandberg K, Westbye O, Beerman B, Wærsted A, red. Treatment of ulcer and gastrooesophageal reflux. Workshop. Stockholm/Oslo: Läkemedelsverket/Statens legemiddelkontroll, 1994; I: 205-14.